ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0557

The Beta Secretase BACE1 Induces Systemic Sclerosis (SSc) Fibroblast Activation Through the Regulation of the Pro-Fibrotic Notch Signalling Pathway

Christopher Wasson1, Eva Clavane2, Rebecca Ross1, Paul Meakin2 and Francesco Del Galdo3, 1LIRMM University of Leeds, Leeds, United Kingdom, 2LICAMM University of Leeds, Leeds, United Kingdom, 3University of Leeds, Leeds, United Kingdom

Meeting: ACR Convergence 2021

Keywords: Fibroblasts, Dermal, Scleroderma, skin, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Systemic Sclerosis & Related Disorders – Basic Science Poster (0541–0559)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Extensive work in the Alzheimer’s field has shown BACE1 plays an important role in amyloid beta processing. Additionally, there is evidence showing BACE1 regulating Notch signalling and disrupting angiogenesis in the context of Alzheimer’s. Given the known role of Notch signalling and disrupted angiogenesis in Systemic Sclerosis (SSc), in this study we investigated the role of BACE1 in the profibrotic phenotype of dermal fibroblasts from SSc skin.

Methods: Dermal fibroblasts were obtained from full thickness skin biopsies from early-diffuse cutaneous SSc patients. Protein was collected from the fibroblasts and BACE1 protein levels were assessed by western blot. SSc patient fibroblasts were treated with the BACE1 inhibitor M3.

Results: BACE1 protein levels were found to be expressed at significantly higher levels in SSc patient fibroblasts compared to healthy controls (1.9-Fold). Inhibition of BACE1 with the specific small molecule inhibitor led to reduced myofibroblast marker (Collagen type 1, alpha smooth muscle actin and CTGF) expression in SSc fibroblasts. Further analysis found inhibition of BACE1 could block the morphogen (TGF-b, Sonic hedgehog and Wnt-3a) mediated fibroblast activation. The BACE1 inhibitor reduced alpha smooth muscle actin expression in TGF-b stimulated fibroblasts by 50%, in sonic hedgehog stimulated cells by 65% and in Wnt-3a stimulated cells by 35%. Finally, treatment of SSc fibroblasts with the BACE1 small molecule inhibitor resulted in reduced expression of the active form of Notch1 and downstream targets Hes1 and GLI2, suggesting BACE1 contributes to SSc fibroblast phenotype through the activation of Notch signalling pathway.

Conclusion: We have identified a novel role for BACE1 in SSc myofibroblast activation through Notch1. This further strengthen the important role Notch signalling plays in SSc. Furthermore, this study highlights BACE1 as a potential novel antifibrotic target for therapeutic intervention which could be investigated with a number of BACE1 inhibitors currently in clinical trials for Alzheimer’s.


Disclosures: C. Wasson, None; E. Clavane, None; R. Ross, None; P. Meakin, None; F. Del Galdo, Boehringer-Ingelheim, 1, 2, 5, 6, Astra-Zeneca, 1, 2, 5, 6, Jannsenn, 6, Chemomab, 2, 5, Capella Biosciences, 2, 5, Mitsubishi-Tanabe, 2, 5.

To cite this abstract in AMA style:

Wasson C, Clavane E, Ross R, Meakin P, Del Galdo F. The Beta Secretase BACE1 Induces Systemic Sclerosis (SSc) Fibroblast Activation Through the Regulation of the Pro-Fibrotic Notch Signalling Pathway [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/the-beta-secretase-bace1-induces-systemic-sclerosis-ssc-fibroblast-activation-through-the-regulation-of-the-pro-fibrotic-notch-signalling-pathway/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-beta-secretase-bace1-induces-systemic-sclerosis-ssc-fibroblast-activation-through-the-regulation-of-the-pro-fibrotic-notch-signalling-pathway/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology